Screener
Edgewise Therapeutics, Inc. EWTX Other operating expenses
Other operating expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $42,651 | $36,757 |
| General and administrative | 11,464 | 9,202 |
| Total operating expenses | 54,115 | 45,959 |
| Loss from operations | (54,115) | (45,959) |
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s other operating expenses?
- Edgewise Therapeutics, Inc. (EWTX) reported other operating expenses of $54.12M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Edgewise Therapeutics, Inc.'s other operating expenses increased by 17.7% year-over-year, from $45.96M to $54.12M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s other operating expenses has grown at a 45.1% compound annual growth rate (CAGR), from $43.22M to $191.41M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Edgewise Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude